{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T02:11:43.405409+00:00","company":{"ticker":"CTSO","cik":1175151,"company_name":"Cytosorbents Corp"},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"cccde76915b976920347c3e85e816d7a314e5111","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2026-04-02T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-09-28","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2026-04-01","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":"Minimum Bid Price Requirement as set forth in Nasdaq Listing Rule 5550(a)(2) in accordance with Nasdaq Listing Rule 5810(c)(3)(A)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Cytosorbents Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-038859","anchor_url":"https://secwatch.observer/filing/0001104659-26-038859#claim-cccde76915b976920347c3e85e816d7a314e5111","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"b2069e9c4056b2bcadade0a68fc4292388c7a405","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2025-10-03T23:59:59+00:00","payload":{"company_response":"The Company intends to actively monitor the closing bid price of its common stock, and will consider its options to regain compliance with the Minimum Bid Price Requirement.","compliance_status":"deficient","cure_deadline":"2026-03-31","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-10-02","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Cytosorbents Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"October 2, 2025, CytoSorbents\nCorporation (the “Company”) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market\nLLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common\nstock had fallen below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The written notification has\nno immediate effect on the listing or trading of the Company’s common stock. In accordance with applicable Nasdaq rules, the Company\nhas 180 calendar days following the date of the written","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-096675","anchor_url":"https://secwatch.observer/filing/0001104659-25-096675#claim-b2069e9c4056b2bcadade0a68fc4292388c7a405","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925096675/0001104659-25-096675-index.htm"},{"fact_type":"executive_change","fact_key":"30b1c0d47b","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2024-08-16T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-08-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Peter J. Mariani","successor_named":true},"claim":"Kathleen P. Bloch retired as Chief Financial Officer at Cytosorbents Corp.","evidence_excerpt":"the Company also announced the retirement of Ms. Kathleen P. Bloch, the Company’s then serving Chief Financial Officer, and her transition into a consulting role with the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-090567","anchor_url":"https://secwatch.observer/filing/0001104659-24-090567#claim-30b1c0d47b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/0001104659-24-090567-index.htm"},{"fact_type":"executive_change","fact_key":"a6327df306","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2024-08-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Peter J. Mariani was appointed as Chief Financial Officer at Cytosorbents Corp.","evidence_excerpt":"On August 13, 2024, CytoSorbents Corporation (the “Company”) issued a press release announcing the appointment of Peter J. Mariani as the Company’s new Chief Financial Officer, effective as of August 14, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-090567","anchor_url":"https://secwatch.observer/filing/0001104659-24-090567#claim-a6327df306","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/0001104659-24-090567-index.htm"},{"fact_type":"earnings_release","fact_key":"86be61befea2ff581598fa51340e2fbff38d74d4","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$9.8 million"},"claim":"Cytosorbents Corp reported the quarter ended March 31, 2024 results: revenue $9.8 million.","evidence_excerpt":"$7.9 million in Q1 2023, an increase of 14%, and up 22%\nsequentially from $7.3 million in Q4 2023 · Total revenue, including product sales and grant income, for Q1 2024 was $9.8 million, an increase of\n4% compared to $9.4 million in Q1 2023 · Q1 2024 product gross margins increased to approximately 76%, (excluding the impact of a one-time,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059457","anchor_url":"https://secwatch.observer/filing/0001104659-24-059457#claim-86be61befea2ff581598fa51340e2fbff38d74d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/0001104659-24-059457-index.htm"},{"fact_type":"governance_change","fact_key":"b1b26ab1137d8348f8dd5e777bebed1190e6c359","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2024-05-06T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-05-02","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to delete stockholder list examination requirement, update advance notice disclosure requirements, delete requirement for stockholder action at meetings, and add forum selection clause"},"claim":"Cytosorbents Corp: Amended and restated bylaws to delete stockholder list examination requirement, update advance notice disclosure requirements, delete requirement for stockholder action at meetings, and add forum selection clause (effective 2024-05-02).","evidence_excerpt":"On May 2, 2024, the Board of Directors (the “Board”) of CytoSorbents Corporation (the “Company”) approved the Second Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-057514","anchor_url":"https://secwatch.observer/filing/0001104659-24-057514#claim-b1b26ab1137d8348f8dd5e777bebed1190e6c359","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924057514/0001104659-24-057514-index.htm"},{"fact_type":"earnings_release","fact_key":"13cea5277e1b89a7286977552d57b71a9bac3566","cik":1175151,"ticker":"CTSO","company_name":"Cytosorbents Corp","filed_at":"2024-03-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter and year ended December 31, 2023","report_date":"2024-03-14","result_type":"reported_results","revenue_text":"$36.3 million"},"claim":"Cytosorbents Corp reported quarter and year ended December 31, 2023 results: revenue $36.3 million.","evidence_excerpt":"quarter\nand year ended December 31, 2023 and provides its 2024 outlook. Full Year 2023 Financial Results · 2023 Total Revenue, which includes Product Sales and Grant Income, was $36.3 million versus $34.7\nmillion in 2022, an increase of approximately $1.7 million or 5% · Total product sales were $31.1 million in 2023 versus $29.4 million in 2022, an increase of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-034674","anchor_url":"https://secwatch.observer/filing/0001104659-24-034674#claim-13cea5277e1b89a7286977552d57b71a9bac3566","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm"}]}